Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-7000
¥ millionWording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 8 May 2025Net Sales173,000→166,000million
-4.0%
Operating profit30,000→30,000million
0.0%
Profit attributable to owners of the parent24,000→24,000million
0.0%
Net income per share356.2→356.2yen and sen
0.0%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
2026年3月期中に発売を見込んでいたCAP-1002について、2025年7月にカプリコール・セラピューティクス社が米国FDAよりComplete Response Letterを受領し、発売時期が未定となったため、通期の売上収益は前回発表予想を下回る見込みとなった。
Dividend forecast revisionNo revision
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | ¥173,000 million → ¥166,000 million（-4.0%） |
| Operating profit | ¥30,000 million → ¥30,000 million |
| Profit attributable to owners of the parent | ¥24,000 million → ¥24,000 million |
| Net income per share | 356.2 yen and sen → 356.2 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 8 May 2025 |
| Reason for the revision | 2026年3月期中に発売を見込んでいたCAP-1002について、2025年7月にカプリコール・セラピューティクス社が米国FDAよりComplete Response Letterを受領し、発売時期が未定となったため、通期の売上収益は前回発表予想を下回る見込みとなった。 |
| Dividend forecast revision | No revision |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
Ordinary incomePrevious-period resultsDetails and amount of extraordinary loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.2026年3月期中に発売を見込んでいたCAP-1002について、2025年7月に提携先が米国FDAからComplete Response Letterを受領し、発売時期が未定となったため、通期の売上収益が前回予想を下回る見込みとなった。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.